Virus-Free Gene Therapy Vector for Safe Therapeutic Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for conditions like epidermolysis bullosa face challenges due to the presence of antibiotic resistance genes and viral regulatory elements in DNA vectors, which can lead to immune responses and reduced efficiency, and existing vectors are not optimized for safe and effective expression of KRT5, KRT14, LAMB3, and COL7A1 genes.
Innovation Solution
Development of gene therapy DNA vectors, such as VTvaf17, that lack antibiotic resistance genes and viral regulatory elements, allowing for safe and efficient expression of KRT5, KRT14, and COL7A1 genes by using a 3165 bp vector design optimized for penetration into eukaryotic cells, with a method for industrial-scale production using Escherichia coli strain SCS110-AF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional DNA vectors containing antibiotic resistance genes and viral regulatory elements are used, then gene expression can be achieved, but immune responses are triggered and safety is compromised
Solution Approach 1:
The patent removes antibiotic resistance genes and viral regulatory elements from the DNA vector structure. The minimal origin of replication (ori) contains only essential sequences (5'-GAGGCTGCTGCTCCTGCCTGTTCCTAGGGGATCCCCGAGGCTGCTGCTCCTG-3' and complementary strand) required for E. coli replication, eliminating harmful foreign genetic elements while maintaining vector functionality.
Solution Approach 2:
The patent fundamentally changes the compositional parameters of the DNA vector by using a synthetic minimal origin of replication instead of traditional viral origins. This parameter change reduces the vector size and eliminates immunogenic viral sequences, transforming the vector from a complex viral-based structure to a streamlined bacterial-origin-based structure that is safer for eukaryotic cell transfection.
2Productivity
If DNA vectors are optimized for small size to improve penetration into eukaryotic cells, then transfection efficiency increases, but production complexity may increase
Solution Approach 1:
The patent segments the DNA vector into distinct functional modules: a minimal origin of replication (ori) containing only essential replication sequences, a multiple cloning site (MCS) for therapeutic gene insertion, and necessary regulatory elements. This segmentation allows for compact design while maintaining all essential functions, achieving small size without excessive complexity.
Solution Approach 2:
The minimal origin of replication is designed to serve multiple functions: enabling plasmid replication in E. coli for production, maintaining plasmid stability during storage and handling, and allowing efficient extraction and purification. This multi-functionality reduces the need for additional viral elements, keeping the vector compact while versatile.
3Ease of manufacture
If antibiotic resistance genes are included in DNA vectors for selection during production, then ease of manufacture improves, but safety and immunogenicity are compromised
Solution Approach 1:
The patent completely extracts and removes antibiotic resistance genes from the vector structure. Instead of relying on antibiotic selection markers, the system uses a minimal origin of replication that enables natural bacterial selection through plasmid maintenance, eliminating the need for antibiotic resistance genes and associated safety concerns.
Solution Approach 2:
The minimal origin of replication acts as an intermediary mechanism that replaces the function of antibiotic resistance genes. It enables selective pressure during production through plasmid stability and replication efficiency rather than through antibiotic resistance, serving as a safe alternative mediator for production selection.
Data Source
AI summary
The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaf1V carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB 3, and COL7A1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvaf17-KRT5, or VTvaf17-KRT14, or VTvaf17-LAMB3, or VTvaf17-COL7A1 has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals. A method of obtaining the specified vector, the use of the vector, a strain of Escherichia coli carrying the specified vector, and a method of industrial production of the specified vector are also provided.